EMJ Podcast: Insights For Healthcare Professionals

In this first deep dive, Vallier discusses the current state of liver regeneration research. He explores how pluripotent stem cells can generate hepatocytes and biliary cells, and describes how organoids integrate into tissues whilst providing new insights into liver disease.

Timestamps:

00:53 – Liver regeneration at present

03:37 – Pluripotent stem cells

05:18 – Scaling clinical use of organoids

06:42 – Application to non-alcoholic fatty liver disease

09:22 – Ethical considerations

Ludovic Vallier joins the EMJ Podcast to answer rapid-fire questions about how regenerative technologies can be harnessed to tackle metabolic liver disease. From the biggest breakthroughs in regenerative hepatology to clinical misconceptions about stem cells, explore how this field of research is changing the liver disease landscape.

In the final episode, Gerber discusses how discoveries move from laboratory research into real-world patient care. Drawing on his experience in clinical trials, entrepreneurship, and national transplant policy, he shares insights into the future of transplantation and regenerative surgery.

Timestamps:

Pullquote and timestamps:

00:56 – Clinical trials

02:42 – Entrepreneurship in life sciences

04:13 – Academic institution support

06:28 – Improving organ allocation

08:02 – Future of transplant surgery

In this second deep dive, Gerber discusses his appointment as Chair of Surgery at the University of Cincinnati, Ohio, USA, and his vision for advancing a century-long legacy of excellence. He reflects on how military and academic leadership shaped his approach to mentorship and accountability, explores the future of equity in surgical training, and offers advice to aspiring academic leaders.

Timestamps:

01:00 – Role as Chair of Surgery

02:55 – Building legacy

04:50 – Military experience

07:13 – Makeup of surgery trainees

09:09 – Early career advice

In this episode, Robin Jones explores the complexities of sarcoma care, reflecting on his career journey, the challenges of diagnosis, and the evolving treatment landscape. The discussion spans unmet needs, promising research, and what the next decade may hold for patients with both localised and metastatic sarcomas, drawing on experience from clinical practice and trials across the UK and USA.

Timestamps:

00:00 – Introduction

00:57 – Robin's career journey

01:43 – Why sarcoma?

03:05 – Different types of sarcomas

05:09 – Diagnosis and treatment decision-making

07:19 – Challenges in recognising sarcoma

10:34 – Evolution of care for patients

13:10 – Promising therapies and research

15:25 – Working across the UK and USA

16:32 – Current unmet needs for patients

18:42 – The future of sarcoma care

21:34 – Robin's magic wishes for healthcare

In this episode, Robin Jones explores the complexities of sarcoma care, reflecting on his career journey, the challenges of diagnosis, and the evolving treatment landscape. The discussion spans unmet needs, promising research, and what the next decade may hold for patients with both localised and metastatic sarcomas, drawing on experience from clinical practice and trials across the UK and USA.

Timestamps:

00:00 – Introduction

00:57 – Robin's career journey

01:43 – Why sarcoma?

03:05 – Different types of sarcomas

05:09 – Diagnosis and treatment decision-making

07:19 – Challenges in recognising sarcoma

10:34 – Evolution of care for patients

13:10 – Promising therapies and research

15:25 – Working across the UK and USA

16:32 – Current unmet needs for patients

18:42 – The future of sarcoma care

21:34 – Robin's magic wishes for healthcare

In this first deep dive, Gerber explores how regenerative medicine is reshaping transplant surgery. He discusses advances in stem cell biology, tissue engineering, and ex vivo organ preservation, and examines how these technologies may expand organ viability and redefine surgical repair.

Timestamps:

01:18 – Tissue regeneration

02:19 – Evolution beyond traditional transplantation

04:04 – Ex-vivo organ preservation

05:09 – Extending organ viability

06:34 – Promising frontiers

09:04 – Bench to bedside

David A. Gerber joins the EMJ Podcast for a rapid-fire discussion on what drives innovation in transplant surgery. From misconceptions about organ transplantation to the technologies shaping the future of regenerative medicine, this episode offers a concise overview of a rapidly evolving field.

This podcast was developed and funded by AbbVie and is intended only for healthcare professionals experienced in the diagnosis and treatment of inflammatory bowel disease.

Please note that this podcast was developed in accordance with the UK and EU risankizumab SMPCs

Click here for UK risankizumab 360 mg and 600 mg prescribing information.

Full Summary of Product Characteristics (SmPC) for Skyrizi (risankizumab) available here: EU – Spain – Germany – Brazil.

Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Please be aware that the label within your country may differ due to local regulations, and you should always consult your own label for prescribing and safety information about risankizumab.

In this podcast, listen to Laurent Peyrin-Biroulet's insights into the latest data from the SEQUENCE trial, including implications for clinical practice.1,2

Listen as we explore:

• The objective and design of the SEQUENCE trial: A head-to-head, open-label Phase 3b trial comparing risankizumab and ustekinumab in patients with moderate-to-severe Crohn's disease who previously failed anti‑TNF therapy1
• The primary endpoints in SEQUENCE were:1
  • CDAI Clinical Remission at Week 24 (Non-inferiority of risankizumab vs. ustekinumab)*
  • Endoscopic Remission at Week 48 (Superiority of risankizumab vs. ustekinumab)
• SEQUENCE 1-year open-label extension data presented at the 2025 European Crohn's and Colitis Organisation (ECCO) Congress2

In this final deep dive episode, Stuart Elborn turns to healthcare systems and policy. He discusses the importance of registries, data sharing, and service organisation, alongside social and funding factors that shape equitable cystic fibrosis care, ending with a global vision for cystic fibrosis management over the next decade.

Timestamps:

00:00 – Introduction

01:08 – Healthcare delivery

03:33 – National registries

05:04 – New challenges

06:35 – Equitable care

08:51 – Regional initiatives

10:40 – What's next?